{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:56:16Z","timestamp":1758279376823},"reference-count":30,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1185\/030079905x56529","type":"journal-article","created":{"date-parts":[[2005,7,28]],"date-time":"2005-07-28T08:57:59Z","timestamp":1122541079000},"page":"1307-1315","source":"Crossref","is-referenced-by-count":22,"title":["The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL\u2010C Value \u2013 an Evaluation of Rosuvastatin therapY compared with atorvastatin"],"prefix":"10.1185","volume":"21","author":[{"given":"Francisco A. H.","family":"Fonseca","sequence":"first","affiliation":[]},{"given":"Alvaro","family":"Ruiz","sequence":"additional","affiliation":[]},{"given":"Ernesto G.","family":"Cardona-Mu\u00f1oz","sequence":"additional","affiliation":[]},{"given":"Jose M.","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Nery","family":"Fuenmayor","sequence":"additional","affiliation":[]},{"given":"Marcelo","family":"Marotti","sequence":"additional","affiliation":[]},{"name":"for the DISCOVERY PENTA investigators","sequence":"additional","affiliation":[]}],"member":"301","published-online":{"date-parts":[[2005,7,19]]},"reference":[{"doi-asserted-by":"publisher","key":"CIT0001","DOI":"10.1016\/0002-9343(84)90952-5"},{"key":"CIT0002","first-page":"11","volume":"90","author":"Wilson PW","year":"1991","journal-title":"Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med"},{"key":"CIT0003","first-page":"237","volume":"2","author":"Assmann G","year":"1997","journal-title":"New and classical risk factors \u2013 the Munster heart study (PROCAM). Eur J Med Res"},{"key":"CIT0004","first-page":"1383","volume":"344","author":"Anon","year":"1994","journal-title":"Lancet"},{"doi-asserted-by":"publisher","key":"CIT0005","DOI":"10.1056\/NEJM199511163332001"},{"doi-asserted-by":"publisher","key":"CIT0006","DOI":"10.1056\/NEJM199610033351401"},{"doi-asserted-by":"publisher","key":"CIT0007","DOI":"10.1001\/jama.279.20.1615"},{"key":"CIT0008","first-page":"1349","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease","year":"1998","journal-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med"},{"doi-asserted-by":"publisher","key":"CIT0009","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"CIT0010","first-page":"1149","volume":"361","author":"Sever PS","year":"2003","journal-title":"Prevention of coronary and stroke events with atorvastatin in hyper tensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial \u2013 Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet"},{"doi-asserted-by":"publisher","key":"CIT0012","DOI":"10.1001\/archinte.160.4.459"},{"doi-asserted-by":"publisher","key":"CIT0013","DOI":"10.1053\/euhj.2001.2610"},{"doi-asserted-by":"publisher","key":"CIT0014","DOI":"10.1001\/jama.285.19.2486"},{"doi-asserted-by":"publisher","key":"CIT0016","DOI":"10.1185\/030079902125000787"},{"key":"CIT0017","first-page":"1772","volume":"44","author":"Koren MJ","year":"2004","journal-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol"},{"doi-asserted-by":"publisher","key":"CIT0018","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"CIT0019","first-page":"689","volume":"19","author":"McKenney JM","year":"2003","journal-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin"},{"key":"CIT0020","first-page":"705","volume":"147","author":"Schuster H","year":"2004","journal-title":"Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J"},{"doi-asserted-by":"publisher","key":"CIT0021","DOI":"10.1016\/j.amjcard.2004.06.049"},{"key":"CIT0022","first-page":"499","volume":"18","author":"Friedewald WT","year":"1972","journal-title":"Estimation of the con centration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem"},{"doi-asserted-by":"publisher","key":"CIT0023","DOI":"10.1053\/euhj.1998.1243"},{"key":"CIT0026","first-page":"29","volume":"21","author":"Bots AFE","year":"2004","journal-title":"Tijdschr Huisartsgeneesk"},{"doi-asserted-by":"publisher","key":"CIT0027","DOI":"10.1345\/aph.1D391"},{"key":"CIT0028","first-page":"1495","volume":"350","author":"Cannon CP","year":"2004","journal-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl J Med"},{"key":"CIT0029","first-page":"1425","volume":"352","author":"LaRosa JC","year":"2005","journal-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med"},{"key":"CIT0030","first-page":"1071","volume":"291","author":"Nissen SE","year":"2004","journal-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc"},{"key":"CIT0031","first-page":"227","volume":"110","author":"Grundy SM","year":"2004","journal-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation"},{"key":"CIT0032","first-page":"79","volume":"92","author":"Foley KA","year":"2003","journal-title":"Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol"},{"key":"CIT0035","first-page":"2292","volume":"108","author":"Ridker PM","year":"2003","journal-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Rationale and design of the JUPITER trial. Circulation"},{"doi-asserted-by":"publisher","key":"CIT0038","DOI":"10.1016\/j.amjcard.2004.09.034"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079905X56529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T08:44:49Z","timestamp":1481618689000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079905X56529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,19]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2005,6,17]]},"published-print":{"date-parts":[[2005,8]]}},"alternative-id":["10.1185\/030079905X56529"],"URL":"https:\/\/doi.org\/10.1185\/030079905x56529","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"type":"print","value":"0300-7995"},{"type":"electronic","value":"1473-4877"}],"subject":[],"published":{"date-parts":[[2005,7,19]]}}}